- NCIt
- C121671
Loading cancer entity…
Loading cancer entity…
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 |
| clinicaltrials |
| NCT06715579 | Cardiac Angiosarcoma International Registry(CAIR) | recruiting | — | 500 | Immune Oncology Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 8, 2026source: clinicaltrials